How vaccine hesitancy could impact the roll-out of the future COVID-19 vaccine

Podcast

Contemporary Pediatrics sat down with Andrew J. Schuman, MD, to discuss vaccine hesitancy and how those sentiments could impact the future COVID-19 vaccine.

Vaccine hesitancy and vaccine refusal have long been a problem in pediatrics. Last year's measles epidemic served as a signal of what the sentiments could mean for a disease that had been considered vanquished. What could they mean for COVID-19?

Contemporary Pediatrics sat down with Andrew J. Schuman, MD, to discuss vaccine hesitancy and how those sentiments could impact the future COVID-19 vaccine.

Recent Videos
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Tina Tan, MD
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics

FDA approves clesrovimab to protect infants during first RSV season

Joshua Fitch, Senior Editor
June 9th 2025
Article

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels | Image Credit: © Monir - © Monir - stock.adobe.com.

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels

Joshua Fitch, Senior Editor
June 5th 2025
Article

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

CDC: Healthy children can receive COVID-19 vaccine via "shared clinical decision-making" | Image Credit: © ricka_kinamoto - © ricka_kinamoto - stock.adobe.com.

CDC: Healthy children can receive COVID-19 vaccine via 'shared clinical decision-making'

Joshua Fitch, Senior Editor
June 2nd 2025
Article

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.

Expert reactions to new COVID-19 vaccine policies

Expert reactions to new COVID-19 vaccine policies

Joshua Fitch, Senior Editor
May 30th 2025
Article

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

© 2025 MJH Life Sciences

All rights reserved.